QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RVMD

QT64Revolution Medicines, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
162.99
+5.22+3.31%
OverviewShort InterestFilings
RVMDQT64Revolution Medicines, Inc.·NASDAQ
OverviewShort InterestFilings
162.99+3.31%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89RPRX-1.38%$52.96
Snapshot
Index-P/E-EPS (ttm)
-3.04
Insider Own3.70%
Shs Outstand212.60M
Perf Week9.22%
Market Cap33.54BForward P/E-EPS next Y-5.48Insider Trans0.18%Shs Float-Perf Month10.65%
Enterprise Value33.54BPEG0.47EPS next Q-1.96Inst Own-Short Float-Perf Quarter64.16%
Income-1472461793.00P/S0.00EPS this Y-161.54%Inst Trans-Short Ratio-Perf Half Y110.15%
Sales-P/B20.84EPS next Y31.04%ROA-60.86%Short Interest-Perf YTD104.63%
Book/sh7.06P/C-EPS next 5Y-ROE-83.22%52W High166.50 -2.11%Perf Year316.43%
Cash/sh8.97P/FCF-EPS past 3/5Y-ROIC-70.02%52W Low34.00 379.38%Perf 3Y-
Dividend Est.-EV/EBITDA-25.43Sales past 3/5Y-Gross Margin0.00%Volatility2.57% 2.73%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-97.49%Oper. Margin0.00%ATR (14)6.50Perf 10Y-
Dividend Ex-Date-Quick Ratio6.80Sales Y/Y TTM-Profit Margin0.00%RSI (14)61.65Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.80EPS Q/Q-102.65%SMA205.70%Beta1.20Target Price165.75
Payout0.00%Debt/Eq0.29Sales Q/Q-SMA5011.26%Rel Volume1.35Prev Close157.77
Employees616LT Debt/Eq0.09EarningsAug 05SMA20071.24%Avg Volume3.49MPrice162.99
IPO DateFeb 13, 2020Option/ShortYes / YesEPS/Sales Surpr.-24.46% -Net Debt/EBITDA0.00Volume4,699,845Change3.31%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-09-26ReiteratedUBSBuy$170 → $175
Jun-02-26ReiteratedRBC CapitalOutperform$162 → $182
Jun-01-26ReiteratedH.C. Wainwright$169 → $195
Jun-01-26ReiteratedOppenheimerOutperform$165 → $195
May-21-26InitiatedBernsteinMarket Perform$151
May-18-26ReiteratedTruist Financial$99 → $179
May-07-26ReiteratedGuggenheimBuy$175 → $205
Apr-14-26ReiteratedEvercore ISI$140 → $200
Apr-14-26ReiteratedH.C. Wainwright$73 → $169
Apr-14-26ReiteratedRBC CapitalOutperform$140 → $162
Latest News
Jun-18-26
Jun-18-2610:45AM
$1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much TodayBenzinga
Jun-13-26
Jun-13-2605:04AM
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)SeekingAlpha
Jun-10-26
Jun-10-2612:01PM
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $220Benzinga
12:01PM
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $220Benzinga
Jun-09-26
Jun-09-2603:10PM
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk AppetiteSeekingAlpha
03:10PM
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk AppetiteSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2900
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A0170
Gross Profit29-170
Selling, General and Administrative Excl. Other4918797
Research and Development302979592
Other Operating Expense101
Operating Income-323-1,182-690
Interest Expense0240
Unusual Expense
———
Non-Operating Income (Expense)-25-75-89
Net Income Before Taxes-297-1,131-601
Income Taxes00-1
Consolidated Net Income-296-1,131-600
Net Income From Continuing Operations-296-1,131-600
Net Income-296-1,131-600
EPS (Recurring)-3.04-5.95-3.58
EPS (Basic, Before Extraordinaries)-3.04-5.95-3.58
EPS (Diluted)-3.04-5.95-3.58
EBITDA-288-1,091-589
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
601.38——
Gross Margin100.00——
Operating Margin-1,113.79——
Net Margin-1,020.69——
Shares Outstanding107190168
Market Capitalization17,44015,134—
Operating Lease Expense
———
Insider Trading Volume
$178.31$165.09$151.87$138.64$125.42● Close Price0.00M4.61M9.21M13.82M18.42MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Horn Margaret AChief Operating OfficerJun 17 '26Option Exercise27.1459,2001,606,914184,247Jun 17 12:00 AM
Horn Margaret AChief Operating OfficerJun 17 '26Sale160.1229,6004,739,679154,647Jun 17 12:00 AM
Horn Margaret AChief Operating OfficerJun 15 '26Option Exercise32.62120,8003,939,986218,622Jun 17 12:00 AM
Horn Margaret AChief Operating OfficerJun 15 '26Sale160.1760,4009,674,304158,222Jun 17 12:00 AM
Horn Margaret AChief Operating OfficerJun 16 '25Sale98.517,085697,929150,675Jun 17 12:00 AM
Horn Margaret AChief Operating OfficerJun 11 '26Option Exercise40.9320,000818,540168,222Jun 15 12:00 AM
Horn Margaret AChief Operating OfficerJun 11 '26Sale148.0110,0001,480,139158,222Jun 15 12:00 AM
Mancini AnthonySee RemarksMay 26 '26Sale153.993,121480,61154,400May 28 12:00 AM
Mancini AnthonySee RemarksMay 26 '26Option Exercise33.626,242209,856106,109May 28 12:00 AM
Mancini AnthonySee RemarksApr 27 '26Option Exercise33.626,240209,788109,230Apr 29 12:00 AM
Mancini AnthonySee RemarksApr 27 '26Sale132.413,120413,12954,400Apr 29 12:00 AM
GOLDSMITH MARK ASee RemarksApr 15 '26Option Exercise4.61240,0001,105,448424,085Apr 17 12:00 AM
GOLDSMITH MARK ASee RemarksApr 15 '26Sale150.09120,00018,010,488276,698Apr 17 12:00 AM
Mancini AnthonySee RemarksMar 25 '26Sale95.5637,4503,578,82054,400Mar 26 12:00 AM
Mancini AnthonySee RemarksMar 25 '26Option Exercise33.6274,9002,518,138112,350Mar 26 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR